Composition comprising anaerobically cultivated human intestinal microbiota
A technology of intestinal microorganisms and anaerobic culture, applied in the field of composition application, can solve the problems of time-consuming, expensive, ugly, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0104] The microbiota according to the invention were obtained from stool samples from a healthy single donor before 1995. Both the donor and the stool were carefully examined. The functional status of the gut microbiota of the donors was found to have normal functional values for coprosterol, urobilin, mucin, fecal trypsin activity, short-chain fatty acids, and β-aspartylglycine. Tests for hepatitis A virus, hepatitis B virus, hepatitis C virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus (HIV), calicivirus, and rotavirus were all negative. In addition, stool was screened for the presence of Salmonella, Shigella, Campylobacter, Yersinia, Clostridium difficile, and protozoan cysts, and all of these investigations were negative.
[0105] Feces samples (Bristo standard type 2) from the inside of the defecation sample were taken from the above-mentioned healthy donors, and immediately suspended in 30 ml of pre-reduced sterile bacteriological peptone-based...
Embodiment 2
[0143] Fresh or frozen stool samples from individuals not exposed to antibiotics or antibiotic resistance genes (for example, by bacterial infection) were inoculated under anaerobic conditions in 30 ml peptone yeast medium (Difco, USA), which The medium includes animal-derived cholesterol (for example, 1.25% freeze-dried hen egg yolk, Fresenius-Kabi, Sweden), and resazurin as an anaerobic indicator. The composition was re-cultured every two weeks. The bacterial content of the cultured product should be greater than 10 per milliliter of culture medium 6 , preferably greater than 10 9 indivual. The composition can be stored at -70°C after adding 10% glycerol.
Embodiment 3
[0145] A group of 32 patients aged 27-94 years (20 females, median age 78 years; 12 males, median age 75 years) was treated with the composition according to the invention. Of these patients, 22 had underlying chronic diseases such as cancer (breast, colon, prostate) and cardiovascular or lung disease. When recurrent Clostridium difficile infection (RCDI) was first detected, 11 patients took cephalosporin, 9 patients took clindamycin, 4 patients took ciprofloxacin, 2 patients Isoxazole was given to penicillin, 3 other patients were given certain other antibiotics, and finally, 1 patient was given azithromycin. Before receiving the composition according to the invention, 2 patients were not pretreated with specific antibiotics.
[0146] Conventionally, a volume of 30 ml of the invention according to Example 1 is administered rectally via a transrectal catheter in the sigmoid colon or via a colonoscope. Clostridial toxin analysis was performed according to general practice at ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com